---
title: "Jefferies Sticks to Its Buy Rating for Sanofi (SNYNF)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/266598643.md"
description: "Jefferies analyst Benjamin Jackson CFA maintains a Buy rating on Sanofi with a €100.00 price target. Berenberg Bank also reiterated a Buy rating with a €110.00 target. Jackson, who covers the Healthcare sector, has a 10.4% average return and a 71.43% success rate on stock recommendations."
datetime: "2025-11-19T17:05:25.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/266598643.md)
  - [en](https://longbridge.com/en/news/266598643.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/266598643.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/266598643.md) | [繁體中文](https://longbridge.com/zh-HK/news/266598643.md)


# Jefferies Sticks to Its Buy Rating for Sanofi (SNYNF)

In a report released today, Benjamin Jackson CFA from Jefferies maintained a Buy rating on Sanofi, with a price target of €100.00.

### TipRanks Black Friday Sale

-   Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
-   Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off

Jackson CFA covers the Healthcare sector, focusing on stocks such as Galderma Group AG, Sanofi, and Roche Holding AG. According to TipRanks, Jackson CFA has an average return of 10.4% and a 71.43% success rate on recommended stocks.

In a report released on November 6, Berenberg Bank also reiterated a Buy rating on the stock with a €110.00 price target.

### Related Stocks

- [Sanofi (SNYNF.US)](https://longbridge.com/en/quote/SNYNF.US.md)

## Related News & Research

- [Sanofi Secures EU Conditional Marketing Approval for Graft-vs-Host Disease Medicine](https://longbridge.com/en/news/281129645.md)
- [Sanofi’s Sarclisa Subcutaneous Formulation Via On-Body Injector Recommended For EU Approval](https://longbridge.com/en/news/280786871.md)
- [Cigna (CI) Gets a Buy from Bernstein](https://longbridge.com/en/news/281231526.md)
- [LifeSci Capital Keeps Their Buy Rating on Enliven Therapeutics (ELVN)](https://longbridge.com/en/news/280882703.md)
- [Pyxis Oncology (PYXS) Receives a Rating Update from a Top Analyst](https://longbridge.com/en/news/280883162.md)